Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Prostate cancer

Adrenergic receptor b2 (ADRB2); ADRB3; muscarinic acetylcholine receptor M1 (CHRM1; HM1)

Mouse studies suggest inhibiting autonomic nerve development in the tumor microenvironment could help treat and prevent prostate cancer. In mice implanted with bioluminescent human prostate cancer cells, surgical or pharmacological elimination of sympathetic nerves in the prostate or knockout of ADRB2 and ADRB3 prevented tumor initiation. In the mouse model, inhibition of parasympathetic neuron signaling by genetic knockout or pharmacological antagonism of Chrm1 decreased cell invasion and metastasis compared with no inhibition. Next steps include assessing the safety and efficacy of adrenergic and muscarinic inhibitors in the indication.
GlaxoSmithKline plc markets the ADRB2 antagonist Coreg carvedilol to treat heart failure, hypertension and myocardial infarction (MI).
Pfizer Inc. and Akrimax Pharmaceuticals LLC market the ADRB2 antagonist Inderal LA propranolol to treat hypertension.
At least four companies market CHRM1 antagonists to treat incontinence or drooling.

SciBX 6(30); doi:10.1038/scibx.2013.790
Published online Aug. 8, 2013

Patent application filed; available for licensing

Magnon, C. et al. Science;
published online July 12, 2013;
doi:10.1126/science.1236361
Contact: Claire Magnon,
Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y.
e-mail:
clairemagnon1@gmail.com
Contact: Paul S. Frenette,
same affiliation as above
e-mail:
psfrenette@einstein.yu.edu